source
- Taiho and Cullinan's zipalertinib clears Phase 3 trial in EGFR-mutated lung cancerTaiho Oncology and Cullinan Therapeutics announced that their oral EGFR inhibitor zipalertinib successfully completed a registrational Phase 3 study in patients with a specific genetic form of lung…
- Karyopharm faces default risk with only a month left to rescue cancer expansionKaryopharm Therapeutics, a commercial-stage cancer drugmaker, is confronting severe financial strain as its market capitalization is roughly one‑third of the revenue it expects to generate in 2026.…